MedTrace Logo

Retrospective Study of Intensive Therapy Pathways in Children With Cerebral Palsy (P'TI-PARCOURS)

NCT07683455 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2026-07-06

No results posted yet for this study

Summary

This retrospective single-center study aims to describe the care pathways of children with unilateral cerebral palsy (hemiplegia) who participated in intensive therapy programs (COLHEMI and/or Mini-COLHEMI) at the Centre des Massues since January 2010. The COLHEMI program (launched in 2010, for children aged 6-12) provides 70 hours of intensive motor learning-based therapy over 2 weeks, while the Mini-COLHEMI program (launched in 2020, for children from age 2) provides 30 hours over 2 weeks. The study will describe the immediate and medium-term impact of these programs on bimanual performance (Assisting Hand Assessment, AHA) and individualized goal attainment (Goal Attainment Scaling, GAS), analyze their impact on bimanual developmental trajectories using all available AHA scores, identify characteristics of good responders, and describe parent satisfaction. Approximately 75 patients will be included. Data are collected retrospectively from electronic and paper medical records by an occupational therapist.

Conditions

  • Cerebral Palsy
  • Hemiplegia

Interventions

OTHER

COLHEMI program

the COLHEMI program (for children aged 6-12 years; 70 hours of motor learning-based intensive therapy over 2 weeks combining mCIMT, bimanual training, and goal-oriented therapy) and/or the Mini-COLHEMI program (for children from age 2; 30 hours over 2 weeks of 10 half-day sessions)

Sponsors & Collaborators

  • Centre Médico-Chirurgical de Réadaptation des Massues Croix Rouge Française

    lead OTHER

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2027-06-01
Completion
2027-06-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07683455 on ClinicalTrials.gov